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An improved understanding of etiological mechanisms in Parkinson’s disease (PD) is urgently
needed because the number of affected individuals is projected to increase rapidly as
populations age. We present results from a blood-based methylome-wide association study
of PD involving meta-analysis of 229 K CpG probes in 1,132 cases and 999 controls from two
independent cohorts. We identify two previously unreported epigenome-wide significant
associations with PD, including cg06690548 on chromosome 4. We demonstrate that
cg06690548 hypermethylation in PD is associated with down-regulation of the SLC7A11 gene
and show this is consistent with an environmental exposure, as opposed to medications or
genetic factors with effects on DNA methylation or gene expression. These findings are
notable because SLC7A11 codes for a cysteine-glutamate anti-porter regulating levels of the
antioxidant glutathione, and it is a known target of the environmental neurotoxin
β-methylamino-L-alanine (BMAA). Our study identifies the SLC7A11 gene as a plausible
biological target in PD.
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Parkinson’s disease (PD) is a debilitating neurodegenerativedisorder characterized by cytoplasmic and axonal aggrega-tions of alpha-synuclein, known as Lewy bodies, and the
progressive loss of dopaminergic neurons in the substantia nigra
pars compacta (hereafter, substantia nigra) of the midbrain. The
prevalence of PD is estimated to be ~1% in people over the age of
60, increasing to 3–4% at the age of 801. With rising life expec-
tancy worldwide, the number of individuals with PD is expected
to more than double by 20402, leading to an increasingly heavy
social and economic burden. The etiology of PD is complex,
involving both genetic and environmental factors, but the specific
molecular mechanisms contributing to pathogenesis remain
poorly understood. Identifying epigenetic modifications asso-
ciated with PD may provide insights into disease etiology.
DNA methylation at CpG dinucleotides is the most widely
characterized epigenetic mechanism and is essential to normal
development and maintenance of cell- and tissue-specific gene
expression patterns3. Variation in DNA methylation can arise
from environmental4, stochastic5, or genetic6 perturbations, and
there is growing evidence that DNA methylation could mediate
the relationship between these processes in influencing risk of
complex disease7. In the most recent epigenetic study of PD
involving 289 PD cases and 219 controls8, Chuang et al. reported
82 epigenome-wide significant CpG probes associated with dis-
ease, although none remained significant after accounting for
differences in blood cell composition between cases and controls.
Larger-scale studies of DNA methylation from PD case–control
cohorts will be needed for identification of methylation probes
robustly associated with disease risk, independent of cell type
composition.
Here, we report results from analyses of genome-wide blood-
based DNA methylation data in 1638 unrelated individuals (851
PD cases, 787 controls) of European descent from the System
Genomics of Parkinson’s Disease (SGPD) consortium (Supple-
mentary Table 1) and 493 European individuals from the Par-
kinson’s disease, Environment and Gene (PEG) cohort9 (281 PD
cases and 212 controls). We use the Houseman et al.10 algorithm
to impute blood cell count proportions in both the SGPD and
PEG samples and find consistent differences in cell type com-
position between PD cases and controls. We show that a sub-
stantial proportion of the variance in PD status is captured by all
methylation probes jointly and we use the PEG cohort to evaluate
a DNA methylation-based classifier for PD based on the aggre-
gated effect of all CpG probes in the SGPD discovery cohort. We
perform methylome-wide association studies (MWAS) of PD in
the SGPD and PEG data sets using recently developed mixed
linear model-based MWAS methods11, and we identify two
previously unreported DNA methylation associations with PD in
a meta-analysis of the SGPD and PEG MWAS summary data. We
use Summary data-based Mendelian Randomization (SMR)12 to
demonstrate that one of these associations, with CpG probe
cg06690548 in the SLC7A11 gene, is consistent with an envir-
onmental exposure, as opposed to genetic factors influencing
DNA methylation or gene expression.
Results
Analysis of predicted cell type proportions. We first used logistic
regression to determine whether predicted cell type proportions
(CTPs) were associated with PD status in the SGPD data set, after
adjusting for sex and predicted age (Eq. (1), Methods). Compared
with controls, we found that PD cases had more granulocytes
(calculated as the sum of eosinophil and neutrophil proportions,
p < 2 × 10−16), fewer B cells (p= 2.16 × 10−10) and fewer helper
T cells (CD4T p= 2.97 × 10−15, CD8T p= 5.29 × 10−03), con-
sistent with findings in a previous report13 (Fig. 1). In addition, we
observed a deficiency of natural killer cells (NK, p= 7.53 × 10−05)
in PD cases compared with controls (Fig. 1). To investigate whether
significant differences in CTPs between PD cases and controls could
be owing to medication, the relationship between levodopa
equivalent daily dosage (LEDD) and CTPs was investigated in 494
unrelated PD cases from the SGPD cohort for whom data on LEDD
were available. We observed significant correlations (Bonferroni-
adjusted p value threshold= 8.3 × 10−03, correcting for testing of
six cell types) between LEDD and the proportion of granulocytes
(Pearson’s correlation= 0.17, p= 9.38 × 10−05), CD4T cells
(Pearson’s correlation=−0.14, p= 2.08 × 10−03) and CD8T cells
(Pearson’s correlation=−0.15, p= 1.08 × 10−03; Supplementary
Fig. 1), although none of these associations survived after adjusting
for disease duration (Supplementary Fig. 2), which exhibited a
strong and significant association with LEDD (Supplementary
Fig. 3). Moreover, the case–control difference in CTPs was similar
in analyses comparing controls with the most exposed cases (top
10% of LEDD), as to the least exposed cases (bottom 10% of LEDD)
(Supplementary Table 2). These analyses suggest that medication
exposure is unlikely to explain the CTP differences between PD
cases and controls, although we are unable to exclude a small effect
of PD medications on CTPs. For this reason, and because CTP
strongly influences DNA methylation measures, we conservatively
corrected for CTPs in our subsequent analyses.
Phenotypic variance for PD attributable to all probes. Next, we
used the omics restricted maximum likelihood (OREML) method
implemented in OSCA11 to estimate the proportion of pheno-
typic variance for PD captured by all the probes (ρ2) (Eqs. (2) and
(3), Methods). For the SGPD and PEG cohorts, these estimates
were 0.28 (se= 0.05, p= 4.0 × 10−20) and 0.24 (se= 0.12, p=
1.4 × 10−05) on the observed scale (i.e., 0–1), respectively, in
models adjusted for sex, predicted age, predicted smoking expo-
sure, and predicted CTPs.
MWAS of PD in the SGPD data. We then used OSCA to per-
form MOA (mixed linear model-based omic association) and
MOMENT (multi component mixed linear model-based omic
association excluding the target) testing of 263,264 CpG probes
across 1638 unrelated PD cases (N= 851) and controls (N= 787)
of European ancestry from the SGPD study (Eqs. (4) and (5),
Methods). No inflation of the test statistics was observed in either
MOA (λ= 1.01; Supplementary Fig. 4) or MOMENT (λ= 1.04;
Supplementary Fig. 5), indicating that the mixed models effi-
ciently corrected for potential confounding factors, consistent
with simulations11. In the MOA analysis, we identified two
epigenome-wide significant associations with PD (Bonferroni-
adjusted significance threshold, p < 1.9 × 10−07; Fig. 2; Table 1),
the strongest of which was for cg16001422 on chromosome 8
(p = 2.3 × 10−08, PLEC gene; Supplementary Fig. 6; Supple-
mentary Data 1). Using the MOMENT method, which has been
shown to be more robust and reliable than MOA for probes that
are strongly associated with an unknown confounding factor11,
we did not identify any genome-wide significant associations
(Supplementary Fig. 7; Supplementary Data 1).
MWAS of PD in the PEG data. Next, we performed mixed linear
model-based association testing of 242,205 CpG probes in Eur-
opean samples (281 PD cases and 212 controls) from the PEG
cohort (Methods), with no single CpG probe surpassing genome-
wide significance in either the MOA or MOMENT analyses (p <
2.06 × 10−07, Fig. 2, Supplementary Figs. 4, 5, 7; Supplementary
Data 2). Focusing on the MOA results, neither of the two
epigenome-wide significant CpG’s identified in the SGPD cohort
replicated in PEG (prep= 2.5 × 10−02; Table 1), but 17 of the 21
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approximately independent (pairwise R2 < 0.1) CpGs with p < 1 ×
10−04 in the SGPD MWAS showed the same direction of effect in
the PEG analysis (one-sided binomial test, p= 3.6 × 10−03;
empirical p ≤ 6.2 × 10−03 based on 10,000 random samples of 21
CpG probes; Supplementary Fig. 8). These observations are
consistent with post hoc power analyses, which suggest that
samples sizes in excess of 2000–3000 would be required for 80%
power to replicate associations identified in SGPD (Supplemen-
tary Fig. 9). As expected, the effect sizes of CpG probes with p <
5 × 10−06 in the Chuang et al.8 PEG analysis in which methy-
lation was adjusted for blood CTPs were highly correlated with
those in our analysis of the PEG cohort (n= 10 probes, Pearson’s
correlation= 0.93, p= 8.9 × 10−05, Supplementary Fig. 10), as
were the effect sizes of genome-wide significant probes reported
by Chuang et al. in their analysis without adjustment for blood
CTPs (N= 78 shared probes, Pearson’s correlation = 0.77, p <
2.2 × 10−16, Supplementary Fig. 11). However, none of the
78 shared probes was genome-wide significant in our analysis of
the PEG data set, and nor did any single shared probe replicate in
the SGPD data (p < 0.05/78).
MWAS meta-analysis of PD. We next conducted PD MWAS
meta-analyses of MOA and MOMENT results for 229,071 CpG
probes in 1132 PD cases and 999 controls from the SGPD and
PEG cohorts (Methods). We identified two epigenome-wide sig-
nificant probes in the MOA meta-analysis (Bonferroni-adjusted
significance threshold, p < 2.18 × 10−07; Fig. 2; Table 2; Supple-
mentary Fig. 4; Supplementary Data 3), including one not pre-
viously identified in the SGPD MWAS (cg06690548 on
chromosome 4; Supplementary Fig. 12). In the MOMENT meta-
analysis, no single probe was epigenome-wide significant (Sup-
plementary Figs. 5, 7; Supplementary Data 3), but cg06690548
was the most strongly associated probe (beta= 0.92, se= 0.20,
p= 2.3 × 10−06) and the effect sizes of CpGs with p < 1 × 10−04
in the MOA meta-analysis (N= 58) were highly correlated with
those in the MOMENT meta-analysis (Pearson’s correlation=
0.93, p < 2.2 × 10−16, Supplementary Fig. 13). Neither of the two
epigenome-wide significant probes in the MOA meta-analysis
harbored a common SNP in the 3′ 5bp-subsequence of the probe
that could have influenced our results. There was no evidence for
strongly associated probes in known PD genes (e.g., SNCA) in
either the MOA or MOMENT meta-analyses (Supplementary
Data 4).
Summary data-based Mendelian randomization. Next, we used
SMR12 to identify specific genes associated with epigenome-wide
significant methylation probes in the MOA analyses, and to eval-
uate evidence for genetic association between DNA methylation,
gene expression and PD (Methods). Of the two significant probes in
the MWAS meta-analysis based on MOA, and the additional
epigenome-wide significant probe in the discovery MWAS, the only
probe with a significant methylation quantitative trait locus
(mQTL) (p < 5 × 10−08) in either blood or brain was cg06690548 on
chromosome 4. SMR applied to this locus identified a significant
association (Bonferroni-adjusted significance threshold correcting
for 12 tests = 4.2 × 10−03) between cg06690548 hypermethylation
and downregulation of the neighboring gene SLC7A11 (SMR: p=
3.59 × 10−03, Fig. 3 and Supplementary Table 3), but there was no
evidence for a genetic association between PD and either
cg06690548 methylation or SLC7A11 expression (i.e., there was no
evidence that the association of cg06690548 hypermethylation with
PD was owing to genetic factors that influence cg06690548
methylation or SLC7A11 expression). The HEterogeneity In
Dependent Instrument (HEIDI) test12 (p= 0.16) enabled us to rule
out the possibility of an association between cg06690548 and
SLC7A11 expression owing to linkage disequilibrium between two
distinct causal variants.
DNA methylation-based classification of PD. Finally, we
examined the efficacy of a DNA methylation-based classifier for
PD, using SGPD as the discovery sample and PEG as the target
sample (Methods). We obtained best linear unbiased prediction-
based estimates of effect sizes for 263,264 probes from a mixed
linear model-based analysis in SGPD (adjusted for sex, predicted
age, predicted smoking exposure, and predicted CTPs) and used

























Fig. 1 Distribution of predicted blood cell type proportions (CTPs) in PD and controls. Boxplots of predicted blood CTPs in 1638 unrelated European
individuals from the SGPD data set, stratified by PD status (851 PD cases, 787 controls). B cells, p= 2.16 × 10−10; CD4T cells, p= 2.97 × 10−15; CD8T cells,
p= 5.29 × 10−03; eosinophils (eos) cells, p= 1.43 × 10−01; monocytes (mono) cells, p= 2.22 × 10−02; neutrophils (neu) cells, p < 2 × 10−16; natural killer
(NK) cells, p= 7.53 × 10−05; granulocytes, p < 2 × 10−16. P values from logistic regression of PD status on predicted age, sex, and individual cell types.
Granulocytes are calculated as the sum of eosinophil and neutrophil proportions. Boxplot center lines show the median, box limits denote upper and lower
quartiles, whiskers represent 1.5 × interquartile range and individual points show outliers.
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individual in the PEG sample. As expected, methylation profile
scores were positively associated with PD in PEG (Fig. 4a), and in
a logistic regression model adjusted for sex, predicted age, pre-
dicted smoking exposure and predicted CTPs, were found to
capture 2.8% (Nagelkerke R2, p= 7.0 × 10−04) of the variance in
case–control status (on the observed scale). The area under the
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Fig. 2 Manhattan plots of MOA MWAS of PD. a MOA MWAS meta-analysis of PD in the SGPD and PEG cohorts (N= 2131 individuals); b MOA MWAS
of PD in the SGPD data set (N= 1638 individuals); c MOA MWAS for PD in the PEG data set (N= 493 individuals).
Table 1 Epigenome-wide significant probes for PD identified in SGPD.
Chr Probe BP Gene Cohort bMOA seMOA pMOA bMOM seMOM pMOM
8 cg16001422 145022842 PLEC SGPD −3.05 0.54 2.3 × 10−08 −1.04 0.60 8.3 × 10−02
PEG −0.44 0.96 0.65 −8.1 × 10−03 0.91 0.99
10 cg26033520 74004071 ASCC1 SGPD −1.55 0.29 1.3 × 10−07 −1.09 0.29 1.9 × 10−04
PEG −1.17 0.56 0.04 −0.77 0.53 0.15
Results are shown for the two epigenome-wide significant probes in the MOA MWAS of SGPD, together with results for these probes from the MOMENT (MOM) MWAS of SGPD and the MOA and
MOMENT MWAS’s of the PEG replication data. Effect sizes (b) and standard errors (se) from OSCA are not standardized.
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Discussion
In our analysis of blood-based DNA methylation in 1132 PD
cases and 999 controls, we identified two DNA methylation
probes associated with PD using MOA: cg26033520 on chro-
mosome 10 in the vicinity of the ASCC1 (Activating Signal Co-
integrator 1 Complex subunit 1) gene and cg06690548 on chro-
mosome 4 in the promoter of the SLC7A11 (Solute Carrier Family
7 member 11) gene. The latter was also the most strongly asso-
ciated probe in the MOMENT meta-analysis, suggesting that it is
unlikely to be a false positive, despite not surpassing epigenome-
wide significance using that method. Our results are consistent
with previous simulations showing that MOMENT is more reli-
able and robust but slightly less powerful than MOA11.
A particularly interesting finding from the SMR analysis was
that hypermethylation of cg06690548 in PD was associated with
downregulation of SLC7A11 but there was no evidence for a
genetic association between PD and either cg06690548 methyla-
tion or SLC7A11 expression. To our knowledge the SMR method
has not previously been used to rule out a genetic effect
underlying a disease association. The SMR results imply that the
association of cg06690548 with PD is not owing to genetic factors
and so may reflect a PD-related environmental exposure or be a
consequence of disease (e.g., a medication effect). We investigated
the latter possibility by applying MOA (with sex, predicted age,
predicted smoking exposure, and predicted CTPs as covariates) to
data on LEDD in 494 unrelated European PD cases in the SGPD
cohort. We found no evidence for an association of cg06690548
methylation with PD medication dosage (beta= 0.50; s.e.= 0.37,
p= 0.17; unpublished data), although we cannot rule out the
possibility of a brain-specific association.
The SLC7A11 gene encodes a sodium-independent cysteine-
glutamate antiporter known as system Xc- (or xCT). The anti-
porter couples the release of one molecule of intracellular gluta-
mate, which is necessary for excitatory signaling between
neurons, with the uptake of one molecule of extracellular cystine,
which is rate limiting for synthesis of glutathione, the primary
antioxidant in the brain. Downregulation of system Xc- results
in decreased intracellular levels of glutathione14,15, which in
Table 2 Epigenome-wide significant probes identified in the meta-analysis of SGPD and PEG.
Chr Probe BP Gene bMOA seMOA pMOA bMOM seMOM pMOM
4 cg06690548 139162808 SLC7A11 1.09 0.20 6.2 × 10−08 0.92 0.19 2.3 × 10−06
10 cg26033520 74004071 ASCC1 −1.47 0.26 1.6 × 10−08 −1.01 0.25 7.5 × 10−05
Results are shown for the two epigenome-wide significant probes identified in the MOA MWAS meta-analysis, together with results for these probes from the MOMENT (MOM) MWAS meta-analysis.
Effect sizes (b) and standard errors (se) from OSCA are not standardized.
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Fig. 3 Summary data-based Mendelian randomization analyses at the SLC7A11 locus. a The uppermost plot shows −log10(P values) of SNPs from the
PDWBS GWAS meta-analysis63. The red diamonds and blue circles represent −log10(P values) from SMR tests for association of gene expression and
DNA methylation probes with PD, respectively. Neither SLC7A11 nor cg06690548 show evidence for a genetic association with PD. The middle plot
shows −log10(P values) of the SNP associations for gene expression probe ENSG00000151012 (tagging SLC7A11) from the Brain-eMeta eQTL study57.
The bottom plot shows −log10(P values) of the SNP associations for DNA methylation probe cg06690548 from the Brain-mMeta mQTL study57.
b Relationship between effect sizes of mQTLs for cg06690548 from the Brain-mMeta mQTL study57 and the corresponding effect sizes for gene
expression probe ENSG00000151012 from the Brain-eMeta eQTL study57 (SMR, p= 3.59 × 10−03). The red triangle shows the top cis-mQTL, blue circles
indicate cis-mQTLs. Error bars show the standard errors of the SNP effects.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15065-7 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1238 | https://doi.org/10.1038/s41467-020-15065-7 |www.nature.com/naturecommunications 5
turn leads to increased oxidative stress. Disruption of glutamate
signaling has been associated with multiple neurodegenerative
diseases16, and for reasons that are not yet understood, dopa-
minergic neurons in the substantia nigra appear to be especially
susceptible to damage by reactive oxygen species17. This is
notable given that loss of dopaminergic neurons in the substantia
nigra is the hallmark pathology of PD and reduced levels of
glutathione have been reported in the substantia nigra, but not
other brain regions, and in human olfactory neural stem cells in
PD patients compared with aged-matched controls15,18,19. In this
context, our SMR findings suggest that the mechanism under-
lying the association of cg06690548 hypermethylation with PD is
that this causes downregulation of system Xc- (Supplementary
Table 3), resulting in reduced glutathione levels and increased
oxidative stress, thereby triggering degeneration of dopaminergic
neurons in the substantia nigra.
Intriguingly, system Xc-, coded by the SLC7A11 gene, is a
target of the environmental neurotoxin β-methylamino-L-alanine
(BMAA)20, a non-protein amino acid produced by cyanobacteria
(i.e., blue green algae)21. Chronic dietary exposure to BMAA is
believed to be the cause of the amyotrophic lateral sclerosis/
parkinsonism-dementia complex (ALS/PDC) that in the 1950′s
had a 50 to 100-fold higher prevalence in the Chamorro people of
Guam than in developed countries22–25. Support for the BMAA
hypothesis in neurodegeneration has waxed and waned in the
30 years since the hypothesis was first proposed26–30, but there
has been renewed interest in recent years based on diverse evi-
dence, including that dietary exposure to BMAA can induce
neurofibrillary tangles and β-amyloid plaques similar to those in
brain tissues from Chamorros with ALS/PDC31 and that regional
variation in ALS prevalence is associated with cyanobacterial algal
blooms32. The mechanism of BMAA neurotoxicity is thought to
involve competition between BMAA and cystine at the cystine/
glutamate antiporter, leading to reduced uptake of cystine, a
depletion of intracellular glutathione and increased oxidative
stress33. Concurrently, this competition may also lead to excito-
toxicity via elevated glutamate release and activation of metabo-
tropic glutamate receptor 5 (mGluR5)34, and a third possibility is
that BMAA transported by system Xc- may be mis-incorporated
in human proteins in place of l-serine, leading to misfolding and
aggregation35.
Our findings, although not directly implicating BMAA in risk
of PD, are notable for being entirely independent of previous
reports—spanning several decades—for an association of this
molecule with neurodegenerative disease. More research is war-
ranted to determine whether dietary exposure to BMAA results in
hypermethylation of cg06690548, if altered methylation at this
CpG also occurs in the substantia nigra, and whether these
methylation changes are associated with an increase in oxidative
stress in these cells via downregulation of system Xc-. Con-
firmation of a causal link between BMAA exposure and risk of
PD would have significant public health implications, as mon-
itoring and control of BMAA in the food chain may be an effi-
cient and cost-effective intervention for Parkinson’s disease and
other neurodegenerative disorders. We acknowledge that envir-
onmental factors other than BMAA, such as pesticide exposure,
could also plausibly influence cg06690548 methylation and
SLC7A11 expression in PD.
The gene closest to the most significant probe (cg26033520)
identified in our MOA MWAS meta-analysis (ranked 35th out of
>219 K probes in the MOMENT meta-analysis) was ASSC1,
which encodes a subunit of the activating signal co-integrator 1
complex. ASCC1 is a compelling candidate for PD because a
recessive mutation in this gene has been associated with spinal
muscular atrophy with congenital bone fractures-2 (SMABF2)36,
and studies in animal models have demonstrated that ASCC1
knockdown is associated with impaired axonal outgrowth of
alpha-motor neurons, impaired neuromuscular junction forma-
tion and compromised motor functioning36. More generally,
ASCC1 is a transcriptional activator that has an important role in
gene transactivation via multiple transcription factors including
nuclear factor kappa-B (NF-kB). NF-kB has a key role in reg-
ulating the immune response to infection and dysregulated
NF-κB activation has been associated with cancer, inflammatory,
and autoimmune diseases and septic shock37. This is noteworthy
given recent findings from in vivo studies of PD, supporting a role
for immune system dysfunction in disease onset and progression,




























Fig. 4 DNA methylation-based classification of PD. a Density distribution of the SGPD-derived DNA methylation-based classifier in the PEG cohort.
Orange and gray represent the distributions of the z-scaled classifier in PD cases and controls in the PEG cohort (respectively). b Area under the receiver
operator characteristic curve (AUC) of the SGPD-based DNA methylation classifier in the PEG cohort (AUC= 0.70, 95% CI= 0.66–0.75).
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The strongest signal in the SGPD MOA MWAS was for
cg16001422, located in the proximity of the PLEC gene. This
probe failed to replicate in MOA analysis of PEG, did not achieve
epigenome-wide significance in the MOA meta-analysis and was
not supported by MOMENT in SGPD, PEG or the meta-analysis.
Nonetheless, it is noteworthy that PLEC, which encodes a large
polypeptide acting as a crosslinker between actin microfilaments,
microtubules, and intermediate filaments in the cell cytoskele-
ton39, has previously been associated with multiple autosomal
recessive forms of muscular dystrophy, including epidermolysis
bullosa simplex with muscular dystrophy, and muscular dystro-
phy, limb-girdle, autosomal recessive 1740–43. Our results suggest
that further investigations are merited on the role of PLEC in
risk of PD.
The proportion of variance in PD status associated with all the
methylation probes (ρ2) was consistently high in both the SGPD
and PEG cohorts (0.28 and 0.24, respectively), and similar in
magnitude to the variance in PD status explained by common
SNPs (0.28 in SGPD, estimated using the genomic-relatedness-
based restricted maximum likelihood method implemented in the
GCTA software44). Notably, when the two epigenome-wide sig-
nificant probes identified in the MOA SGPD MWAS were fitted
as fixed effects (in addition to sex, predicted age, predicted
smoking exposure, and predicted CTPs) in an OREML analysis of
the PEG data, ρ2 decreased from 0.24 to 0.21. These results imply
that the majority of variance in PD status associated with DNA
methylation is still unaccounted for, and that larger PD MWAS
are likely to identify additional genomic regions associated
with PD.
A DNA methylation classifier based on best linear unbiased
prediction-based effect sizes for all probes from an mixed linear
model analysis of SGPD captured ~2.8% of the variance in PD
case–control status in the PEG data set. This estimate was highly
statistically significant but lower than previously reported adjus-
ted R2 estimates for methylation-based classifiers of other com-
plex traits (e.g., BMI, R2= 12.2% in the Lothian Birth
Cohorts;45,46). The receiver operator characteristic curve is used
in clinical epidemiology to quantify how well medical diagnostic
tests discriminate between affected and non-affected (or controls)
individuals. Accuracy is measured by the area under the receiver
operator characteristic curve (AUC). An AUC of 1 represents a
perfect test, whereas an AUC of 0.5 represents a test with no
discriminatory power. In this study, the AUC of the methylation-
based classifier for PD was estimated at ~ 0.70. This value is
comparable to that of the latest GWAS-based predictors for PD47,
but we do not know if PD-associated methylation differences are
a cause or consequence of the disease. For instance, methylation
differences may be owing to medication effects or to some other
physiological change that occurs as a consequence of having PD.
This has implications for the utility of methylation-based classi-
fiers, as they may differentiate PD cases from controls, but have
no predictive value in terms of identifying individuals at high risk
of PD in the population (i.e., before they develop the disease).
Finally, prior studies of PD13 have reported disease-associated
differences in blood CTPs. We replicated a number of these CTP
differences in analysis of PD cases and controls in our SGPD data,
but nonetheless chose to adjust for CTPs in our MWAS analyses,
owing to the fact that we could not rule out the possibility that PD
medications contributed to these differences. We acknowledge
that this approach is conservative and that true positive methy-
lation associations with PD may have been overlooked as a result.
Further investigations will be needed to establish the extent to
which CTP differences associated with PD are part of the disease
process, as opposed to a consequence of the disease. We also
acknowledge that analysis of whole blood-based DNA is a lim-
itation, given that PD is a disorder of the central and peripheral
nervous system. Analysis of DNA methylation in post-mortem
brain tissues from PD cases and controls should be a future
priority for the field.
In conclusion, we describe two previously unreported associa-
tions between DNAmethylation and PD, including with the ASCC1
gene on chromosome 10 and the SLC7A11 gene on chromosome 4.
These associations provide support for glutamate signaling dis-
ruption, oxidative stress, and neuroinflammation as potential etio-
logical mechanisms contributing to PD. The SLC7A11 association is
especially notable given prior evidence that this gene is a target of
the neurotoxin BMAA. An important caveat of our study is that
epigenome-wide significant associations were only identified with
MOA, which has a higher false positive rate than MOMENT11.
However, we have shown that the two probes achieving epigenome-
wide significance in the MOA meta-analysis were also among the
most strongly associated probes in the MOMENT meta-analysis
(ranks 1 and 35 for cg06690548 and cg26033520, respectively). This
suggests that these associations are unlikely to be false positives, and
that their failure to achieve epigenome-wide significance in
MOMENT is likely owing to the slightly reduced power of this
method relative to MOA11. Our linear mixed model analyses
revealed that a surprisingly high proportion of variance in PD status
was associated with DNA methylation measured in whole blood,
suggesting that studies of DNA methylation in larger PD
case–control cohorts are likely to yield additional discoveries rele-
vant to the disorder. A DNA methylation classifier based on the
SGPD data captured a significant proportion of the variance in PD
status in the independent PEG cohort, but an improved under-
standing of the mechanisms of cause and effect in relation to DNA
methylation probes altered in PD is required prior to the applica-
tion of DNA methylation-based classifiers as a diagnostic tool.
Methods
Study populations. The System Genomics of Parkinson’s Disease (SGPD) cohort
comprises genotype, phenotype, and DNA methylation data for a total of 2333
participants (1292 PD cases, 1041 controls) recruited from three different studies
across Australia and New Zealand: (1) the Queensland Parkinson’s Project (QPP),
(2) the New Zealand Brain Research Institute PD case–control cohort (NZBRI),
and (3) the Sydney PD case–control cohort (SYD).
The QPP cohort includes 1791 participants (867 PD cases, 924 controls) mostly
of European ancestry. PD was diagnosed according to standard criteria48 and
controls consisted of healthy community-based, age-matched volunteers residing
in the same area and from the same ethnic background as the PD patients (N=
507), together with patients’ spouses (N= 266) and siblings (N= 151). Whole
blood or saliva (N= 4) samples were collected at the time of recruitment. A total of
1692 individuals completed the Parkinsonism and related neurological disorders
survey and underwent the same evaluations, which included questionnaires on
demographics, medical history, environmental exposures and the Geriatric
Depression Scale (GDS). In addition, cases undertook a cognition test summarized
by the Unified Parkinson’s Disease Rating Scale (UPDRS) score.
The NZBRI cohort comprises 210 participants (151 PD cases, 59 matched
controls) recruited by the NZBRI. Exclusion criteria for PD patients were prior
history of learning disability, severe head injury, stroke, or other neurological
impairment and major psychiatric complications at the point of study entry. Whole
blood samples were collected at the same time as phenotypic measurements, which
included demographic, medical, and environmental exposure information for all
participants. In addition, cases underwent periodic cognition tests, which included
the Parkinson’s Disease Dementia (PDD) criteria49, the Parkinson’s Disease and
Mild Cognitive Impairment (PD-MCI) criteria50, and the UPDRS score.
In the SYD cohort, 332 participants (274 PD cases, 57 matched controls, 1
individual with missing phenotype) were recruited from the Parkinson’s Disease
Research Clinic, Brain and Mind Research Institute at the University of Sydney. PD
was diagnosed according to the UKPDS Brain Bank clinical diagnostic criteria51.
The PEG study is a large population-based study of PD of mostly rural and
township residents of California’s central valley9. The PEG study comprises of 508
European (289 PD cases, 219 controls) and 64 Hispanic individuals (46 PD cases,
18 controls) for a total of 334 PD cases and 237 controls. Cohort details and DNA
extraction methods are described elsewhere9,13.
Ethics approval and consent to participate. All participants gave written consent.
The QPP study was approved by the Griffith University Human Research Ethics
Committee (ESK0411HREC). The Southern Health and Disability Ethics com-
mittee (New Zealand) approved the NZBRI study protocol (URA/11/08/042; URB/
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09/08/037). The SYD study protocol was approved by the University of Sydney
Human Research Ethics Committee (10963; 2013/945). Approval for analysis of
SGPD samples was granted by the University of Queensland Human Research
Ethics Committee (2011001173). The PEG study was approved by the UCLA
Institutional Review Board (IRB 11–001530).
Genotyping and quality control. DNA samples from SGPD participants and 26
plate controls were genotyped using the Illumina PsychArray-B.bpm (571,054
SNPs) at the QIMR Berghofer Molecular Epidemiology Laboratory. Standard
individual-level and SNP-level quality control was applied to the data. A total of 39
unique samples were excluded from the SGPD data set on the basis of unresolved
sex discrepancies (20 samples), high missing data rate (genotype failure rate 0.03;
17 samples) and sample duplications (PIhat > 0.9; 10 samples). SNP markers were
excluded if they had missing genotype rate >5%, Hardy–Weinberg Equilibrium
(HWE) test p value < 1 × 10−05 in controls, different missing genotype rates
between cases and controls (p value < 1 × 10−05) or low minor allele frequency
(MAF < 0.01). We additionally dropped a total of 5293 duplicated SNPs. This
screen reduced the total number of analyzed SNPs by ~49% (predominantly owing
to the MAF filter), leaving 288,452 SNPs and 2227 individuals (1688 from QPP,
210 from NZBRI, 329 from SYD). We performed multidimensional scaling analysis
on the cleaned SNP data to establish the genetic ancestry of study participants. We
merged the SGPD sample with the HapMap3 data set comprising 988 individuals
across 11 populations and defined Europeans as those falling within ±5 SD of the
mean of the HapMap3 European cluster based on the top two principal compo-
nents. A total of 78 individuals (62 from QPP, 4 from NZBRI and 12 from SYD)
showed evidence for non-European genetic ancestry and were removed. The
cleaned SGPD genotypes were imputed to the Haplotype Reference Consortium52
and then additional filtering was performed to remove SNPs with low MAF < 0.01,
HWE test p value in controls <1 × 10−05 and INFO score <0.3. This screen reduced
the total number of imputed SNPs (~38 million) by 81%, leaving 7,582,086 SNPs
and 2138 individuals of European ancestry (1169 PD cases, 65% male; and 968
controls, 46% male, 1 individual with missing phenotype). These data were used
solely for the purpose of identifying unrelated individuals for inclusion in DNA
methylation analyses, as described below.
DNA methylation and quality control. Whole blood-derived genomic DNA from
a total of 1974 SGPD individuals was bisulphite-converted using the EZ-96 DNA
Methylation kit (Zymo Research). The Human Methylation 450 K BeadChip was
used to assess methylation status at 485,512 CpG sites across the genome. Data
were available on 1704 (820 cases, 884 controls) QPP participants, 210 (151 cases,
59 controls) NZBRI participants, and 60 (30 cases, 30 controls) SYD participants.
Methylation arrays were run in two batches: the first comprising 940 samples (835
QPP, 105 NZBRI) and the second comprising 1034 samples (869 QPP, 105 NZBRI,
60 SYD). Samples were randomly placed with respect to array and array position in
order to minimize the potential for batch effects. Low-quality probes and samples
were excluded from further analysis as described below. Methylation scores for
each CpG site, obtained as a ratio of the intensities of fluorescent signals, are
represented as β-values, which range between 0 and 1; a value of 0 indicates that all
copies of the CpG site in the sample (i.e., all cells) were completely un-methylated,
and a value of 1 indicates that every copy of the site was methylated. Raw intensity
data were background-corrected and normalized using internal controls, and
methylation β-values were generated using the R meffil package. Quality control
(QC) was performed to remove probes with a low (<95%) detection rate at p < 0.01
and those that failed the minimum threshold for the number of beads (N= 3). The
R meffil package was also used to perform sample QC using Illumina recom-
mended thresholds. Samples were dropped if call rate was low (<450,000 probes
detected at p < 0.001), if predicted sex, based on XY probes, did not match reported
sex, and if predicted median methylated signal was more than three standard
deviations from the expected. A total of four individuals whose DNA was extracted
from saliva were also excluded. After these QC steps, methylation β-values were
quantile-normalized with respect to 20 principal components (PCs) generated from
the control matrix and the most variable probes. In addition, normalization was
adjusted for batch, slide, cohort, sentrix row/column, sex, and age. A total of
485,237 probes and 1889 samples (959 PD cases, 930 controls) were retained
following QC. We used the GCTA software44 to generate a genetic relationship
matrix (GRM) using all ~7.5 M imputed QC-pass SNPs, and removed one of each
pair of individuals (total N= 190) with an estimated pairwise genetic relationship
>0.05. Subsequently, the Omics-data-based Complex trait Analysis (OSCA) soft-
ware11 (see http://cnsgenomics.com/software/osca) was used to perform additional
filtering of cross-reactive probes (29,218), X/Y-chromosomes probes (10,711) and
lowly variable probes (sd < 0.02), leaving 263,264 probes and 1638 unrelated
European individuals (851 PD cases, 787 controls) available for analysis.
We downloaded Illumina Infinium Human Methylation 450 K BeadChip data
from 508 European (289 PD cases, 219 controls) and 64 Hispanic individuals (46
PD cases, 18 controls) in the PEG study from GEO (https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE111629), with the purpose of replicating epigenome-
wide significant probes identified in the SGPD EWAS and performing meta-
analysis. We performed DNA methylation QC on the European samples from the
PEG data using the same R meffil pipeline applied to the SGPD data set. Overall, 15
unique European samples were filtered out owing to low call rate (<450,000 probes
detected at p < 0.001; N= 10) or because predicted sex did not match reported sex
(N= 6). After these QC steps, methylation β-values were quantile-normalized with
respect to 15 PCs generated from the control matrix and the most variable probes.
In this study, we chose 15 PCs as opposed to 20 because the variance captured by
PCs 16–20 was minimal. In addition, normalization was adjusted for slide, sentrix
row/column, sex, and age. Finally, cross-reactive probes, X/Y-chromosomes probes
and lowly variable probes (sd < 0.02) were also filtered out leaving 242,205 probes
and 493 European samples available for analysis.
Cell type proportions. The R Meffil package was used to impute blood CTPs
according to the Houseman et al.10 method for each individual in both the SGPD
and the PEG cohorts. Differences in CTPs between PD cases and controls were
then singularly tested through logistic regression of PD status on covariates (pre-
dicted age, sex) to account for possible confounding factors. Specifically, we used
the following model:
y ¼ β0 þ
X
i
βiXi þ e ð1Þ
where y is an n × 1 vector of n individuals representing the log odds that an
individual is a case, i ∈ [1, k] with k being the number of fitted covariates, βi is the
effect of the ith covariate on the phenotype, Xi is the ith independent variable or
covariate and e is a n × 1 vector of residuals. Finally, individual CTPs in 494
unrelated PD cases from the SGPD cohort were regressed on LEDD calculated
accordingly to Tomlinson et al.53. LEDD is a quantitative measure of PD-specific
medication measured as mg/day. In a few instances, exact LEDD was not available
but was reported as a range (e.g., 530–1800 mg); in these cases, LEDD was cal-
culated as the mid-point between the lowest and highest values in the range. Prior
to the regression analysis, LEDD was log-transformed owing to the right skewness
of its distribution and standardized.
OREML analyses. The OREML method implemented in the OSCA11 software is a
model in which a single random effect component is used to estimate the pro-
portion of variance in a specific trait captured by all the DNA methylation probes.
The model can be written as:
y ¼ CβþWuþ e ð2Þ
where y is an n × 1 vector of phenotype values of n individuals (coded as 1 for PD
and 0 for unaffected), C is an n × pmatrix for covariates (e.g., sex, age) with p being
the number of fitted covariates, β is a p × 1 vector of the effects of the fixed
covariates on the phenotype, W is an n × m matrix of m standardized DNA
methylation values, where m is the number of DNA methylation sites, u is an m × 1
vector of the joint effects of all the probes on the phenotype, and e is an n × 1
vector of residuals. The variance-covariance matrix for y can be written as:
var yð Þ ¼ V ¼ WW0σ2u þ Iσ2e ¼ Aσ2o þ Iσ2e ð3Þ
where A (the omics-data-based relationship matrix or ORM) is defined as WW′/m
and σ2o ¼ mσ2u . In such a mixed linear model, σ2o and σ2e are the variance com-
ponents and the amount of variance in the phenotype attributable to all the probes
is defined as ρ2 ¼ σ2o= σ2o þ σ2e
 
. Estimation of the variance components can be
computed using REML54, which in OSCA nomenclature is OREML. In the context
of DNA methylation data, ρ2 parallels the concept of SNP-based heritability as
implemented in GCTA44, with the caveat that association signals of DNA
methylation data may reflect both cause and consequence of disease. Here, esti-
mates of ρ2 were from a model that included both confounder covariates (sex,
predicted age, predicted smoking exposure) and predicted CTPs (with the exclu-
sion of eosinophils).
Mixed linear model-based MWAS of PD. We used two mixed linear model-
based approaches implemented in the OSCA11 software to test for association
between disease status and DNA methylation: MOA and MOMENT. Specifically,
the MOA model is:
y ¼ wibi þ CβþWuþ e ð4Þ
where wi is an n × 1 vector of standardized DNA methylation measures of the
target probe i and bi is the effect of probe i on the phenotype (fixed effect).
Important properties of the MOA model are that the target probe is fitted both as a
fixed effect (bi) and a random effect (the ith element of the vector u) and effect sizes
of probes in the random effect term are assumed to come from a single distribu-
tion. The MOMENT approach differs by partitioning probes, on the basis of their
statistical association with the phenotype in an initial linear regression, into two
random effects with different effect size distributions. This method has been shown
to be more robust to potential confounders than MOA but at the cost of slightly
reduced power11. The MOMENT model is:
y ¼ wibi þ Cβþ
X
j
Wjuj þ e ð5Þ
whereWj is an n × mj matrix of standardized DNA methylation probe values in the
jth group, and mj is the number of DNA methylation sites in the group (excluding
the DNA methylation sites <50 Kb from the probe being tested).
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Application of MOA and MOMENT to the SGPD data set involved analysis of
263,264 DNA methylation probes in 1638 (851 PD cases, 787 controls) unrelated
(estimated pairwise relationship <0.05 calculated using GCTA44) European
individuals, and for the PEG data set involved analysis of 242,205 probes in 493
European individuals (281 PD cases, 212 controls). Prior to association analyses we
regressed DNA methylation measures on known batch effects, which included
sentrix row, column and slide in SGPD, and sentrix row and column only in PEG,
because slide was significantly associated with disease status in that sample. Sex,
predicted age55, predicted smoking exposure (unpublished work) and predicted
CTPs (with the exception of eosinophils) were fitted as fixed effects. We checked
strongly associated probes for the presence of common SNPs, using the masking
manifests provided by Illumina (https://zwdzwd.github.io/InfiniumAnnotation).
MWAS meta-analysis of PD. We performed a MWAS meta-analysis of MOA or
MOMENT results for PD using summary data from the SGPD and PEG cohorts,
comprising analysis of 229,071 common methylation probes in a total of 1132 PD
cases and 999 controls. The analyses were conducted in OSCA, which implements
the conventional inverse-weighted-variance analysis assuming independence
among cohorts. Novel signals of association were those surpassing the Bonferroni-
adjusted significance threshold (p= 0.05/229, 071= 2.2 × 10−07).
Summary data-based Mendelian randomization. The SMR and HEIDI meth-
ods12 were used to identify putative target genes regulated by PD-associated CpG
sites, and to examine evidence for causal relationships between DNA methylation,
gene expression and PD. Specifically, to infer the regulatory role of epigenome-
wide significant probes on PD, we applied the SMR approach to test the hypothesis
that DNA methylation is associated with PD through regulation of gene expres-
sion56. This can be done in the SMR framework by testing the pairwise associations
between epigenome-wide CpG probes and PD, epigenome-wide CpG probes and
genes within 2Mb distance in either directions, and between these genes and PD.
These analyses involved summary-level SNP data, including Brain-eMeta57 eQTL
data (neff= 1194) obtained from the meta-analysis of GTEx brain58, CMC59, and
ROSMAP60 correcting for sample overlap by the MeCS method57, Brain-mMeta
mQTL57 data (neff = 1160) obtained from the meta-analysis of ROSMAP60,
Hannon et al.61, and Jaffe et al.62, and PD GWAS summary data (neff = 308,518)
from the PDWBS meta-analysis63 of 6476 PD cases and 302,042 controls. Con-
sistent with assumptions in the SMR method, we included only genes with at least
one cis-eQTL at PeQTL < 5 × 10−08 in Brain-eMeta, leaving 12 genes for analysis.
DNA methylation-based out-of-sample classification. In the SGPD cohort, we
estimated the aggregated effect of all the probes on disease status using a mixed
linear model, which included sex, predicted age, predicted smoking exposure, and
predicted CTPs as fixed effects, as implemented in OSCA. Subsequently, the best
linear unbiased prediction solutions for the probe effects were calculated and used to
generate DNA methylation profile scores for European individuals in the PEG study.
Using logistic regression adjusted for sex, predicted age and predicted CTPs, we
estimated the proportion of variance in PD status (Nagelkerke R2) in the PEG study
captured by the standardized methylation profile scores. In addition, the classifica-
tion accuracy of the methylation profile scores was evaluated by calculating the AUC.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The SGPD methylation data are available from the Gene Expression Omnibus (GEO)
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145361). The SGPD GRM
and top two genetic principal components, used to identify unrelated European
individuals for inclusion in DNA methylation analyses, are available from (https://
cnsgenomics.com/data/vallerga_et_al_2020_nc/). The SGPD MWAS summary statistics
are also available from (https://cnsgenomics.com/data/vallerga_et_al_2020_nc/). The
PEG methylation data are available from GEO (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE111629).
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